| Ytd | -24.94% | |
| 1y | 106.51% |
| Open | 27.20 | Prev Close | 27.38 | Low | 26.62 | High | 27.32 | Mkt Cap | 2.40B |
| Vol | 252.94K | Avg Vol | 1.40M | EPS | -2.05 | P/E | -13.26 | Forward P/E | -13.05 |
| Beta | 0.68 | Short Ratio | 6.07 | Inst. Own | 109.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 26.62 | 200-d Avg | 31.03 | 1yr Est | 49.00 |
MLYS News
RADNOR, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopha
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid s
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a prot
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conferen
RADNOR, Pa. , June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a bioph
Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundros
RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopha
– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront
Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chro
- Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically mea
RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biophar
- Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontro
AstraZeneca wins FDA approvals for Baxfendy in hypertension and Enhertu in early HER2-positive breas
Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Tr
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript
– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of De
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biophar
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biophar
Wall Street is in full rally mode after July’s inflation data eased fears that tariff-related cost p
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
On Tuesday, 647 companies set new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss a
Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings f
Friday's session saw 104 companies set new 52-week lows.
Monday's session saw 114 companies set new 52-week lows.
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly
On Friday, 497 companies set new 52-week lows.